Helius Medical Technologies, Inc. (HSDT)
| Previous close | 2.6600 |
| Open | 3.5895 |
| Bid | 0.0000 x 0 |
| Ask | 2.5900 x 100 |
| Day's range | 2.3500 - 3.6100 |
| 52-week range | 2.3500 - 14.4500 |
| Volume | |
| Avg. volume | 416,746 |
| Market cap | 2.449M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius’ U.S. registrational program for Portable Neuromodulation Stimulator (PoNS®) in stroke ---- The single-arm study will evaluate PoNS in treating gait and balance deficits in chronic stroke survivors ---- Regulatory submission seeking marketing authorization for stroke expected in
- GlobeNewswire
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government S
- GlobeNewswire
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023. Fourth Quarter and Recent Business Updates Secured Healthcare Common Procedure Coding System (“HCPCS”) Level II codes for the Portable
